Survival after CRS-HIPEC was first reported in a large study where Schneider et al found that both KRAS and BRAF mutations had a worse median cancer-specific survival: 18 months for mutBRAF, 38 months for mutKRAS compared to 52 months for double-wt patients [22]. The gene discussed is KRAS; the disease is cancer.